Syndax and Six Flags Shares Plunge Amid Trial Failure and Safety Incident

Key Facts

1Syndax Pharmaceuticals shares fell 15.7% after its Phase 2 trial of axatilimab failed to meet its primary endpoint.

2Six Flags Entertainment shares dropped 14.4% following a fatal roller-coaster incident at Six Flags Over Georgia.

3Adlai Nortye, Omada Health, and Immunic shares recorded sharp declines without clear identified catalysts.

Syndax Pharmaceuticals shares fell 15.7% to $13.95 on October 13, 2026, after its Phase 2 trial of axatilimab failed to meet its primary endpoint. Financial Modeling Prep reported that the company has decided to end development of the drug for idiopathic pulmonary fibrosis following the trial results. Simultaneously, Six Flags Entertainment shares dropped 14.4% to $10.20 on the same day following a fatal roller-coaster incident at Six Flags Over Georgia.

Other stocks recorded sharp declines on October 13, 2026, without clear identified catalysts, as Adlai Nortye shares fell to $11.76 and Omada Health dropped to $18.30. Regarding prior levels, SNDX closed at $16.55 and FUN closed at $11.92 on October 12, 2026. Immunic shares also declined to $6.89, down from a close of $7.95 on October 12, 2026.